Why the study?
The study was conducted to obtain and investigate the antiviral properties of an intranasal drug formulation combining yeast double-stranded RNA and recombinant human interferon alpha-2b within a delivery system.
Does an intranasal composition of dsRNA and IFN-α2b improve antiviral protection in preclinical models of viral infection compared to individual components?
Population
Mouse L929 and L-68 cell cultures and white outbred ICR male mice
Comparison
Combined dsRNA and IFN-α2b vs dsRNA alone or IFN-α2b alone
Design
In vitro and in vivo preclinical study
Authors
Loading...
Hypothesis-generating for intranasal dsRNA-IFN-α2b synergy; human trials needed before clinical consideration.
Does an intranasal composition of dsRNA and IFN-α2b improve antiviral protection in preclinical models of viral infection compared to individual components?
A novel intranasal formulation combining dsRNA and IFN-α2b demonstrates synergistic antiviral activity in preclinical models of viral infection.
Gamaley et al. (2025) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: